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ABSTRACT

Genome engineering relies on DNA modifying enzymes that are able to locate a
DNA sequence o f interest and initiate a desired genome rearrangement. Currently, the
field predominantly utilizes site-specific DNA nucleases that depend on the host DNA
repair machinery to complete a genome modification task. We show here that genome
engineering approaches that employ self-sufficient, versatile site-specific DNA
recombinase Flp and Cre can be developed into promising alternatives. We demonstrate
that a Flp variant evolved to recombine an FRT-like sequence FL-IL10A, which is located
upstream o f the human interleukin-10 gene, can target this sequence in the model setting
and native HEK293 cells. Similarly, Cre variant evolved to recombine at loxP-like
sequence LL-69058, which is located upstream o f the beta globin gene, can target this
sequence in the model setting o f CHO cells and human HEK293 cells.
The target-specific Flp variant is able to perform the integration reaction but the
efficiency o f the integration reaction in human cells can be enhanced by ‘humanizing’ the
Flp variant gene and by adding the NLS sequence to the recombinase. Cre variant
displays a poor replacement activity in the mammalian cells and thus is fused with TAL
DNA-binding domain to enhance their performance. TAL-Cre variant is able to perform
efficient replacement reaction, when paired with another recombinase (dual RMCE). The
Cre variant replacement activity is observed only when they are fused to the TAL

DNA-binding domain. The TAL-Cre fusion has higher replacement efficiency compared
to no replacement activity with just Cre variant.
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CHAPTER 1

INTRODUCTION

1.1 Background
Human genetic disorders are caused by abnormalities in the genome which are
then passed to offspring. Some o f the genetic disorders that are caused by mutation in a
single gene include sickle cell disease (SCD), cystic fibrosis, neurofibromatosis (NF),
Tay-Sachs disease, Duchenne muscular dystrophy (DMD) and platelet type bleeding
disorder as well as many others. Gene therapy is hoped to cure genetic disorders by
adding the wild type gene or replacing the mutated gene with a wild type gene, restoring
proper function in the cells. Initially, viral vectors were used as gene delivery vehicles but
this approach poses potential risk o f inserting the vector randomly in the genome,
potentially activating the tumor promoting pathways. An alternative to viral vector based
gene therapy could be the correction o f the mutated gene using site-specific
recombinases. These enzymes have been shown to integrate, excise, invert genes, and
replace gene fragments in mammalian cells.
My research aims to use site-specific recombinases for integration and
replacement o f genes in the human genome with the goal o f curing a genetic disease.
Recombinases bind to specific DNA sequences called recombination targets and catalyze
DNA rearrangement. For example, integrase from the bacteriophage lambda, specific to
attP and attB target sequences, catalyze integration o f the viral genome into the bacterial
1
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chromosome. XerCD from the Escherichi coli is specific to the dif target sequence in the
bacterial genome and also dif-like target sequences cer (plasmid C olEl), and psi (plasmid
SC 101) sites. XerCD plays an important role by resolving chromosome and plasmid
dimers. Cre recombinase from bacteriophage P I, specific to the loxP target sequence,
catalyzes the circularization o f linear phage genomes. Flp recombinase that is encoded by
a 2 micron plasmid from Saccharomyces cerevisiae and is specific for the FRT target
sequence, helps in maintaining the plasmid copy number by inverting one part o f the 2
micron plasmid relative to the other part during replication [1-4].
Site-specific tyrosine recombinases are primarily found in the prokaryotes, but
they have also been found in the archaea and some eukaryotes. PSI-BLAST, a computer
software, identifies more than 1000 related sequences o f the tyrosine recombinase family
[3,4]. Therefore, the 3D fold o f tyrosine site specific recombinases is adapted to
recognize a wide variety o f target sequences. This phenomenon can be exploited to
evolve recombinase variants that recognize target-like sequences that resemble the native
target sequences. Such target-like sequences for a recombinase can be found in the
human genome on average every 5000 bp (5 kb) [5], For the purpose o f gene therapy,
target-like sequences can be used as recombination targets to either integrate or replace a
gene region.
Recombinases can be used as tools for genome manipulation. In principle,
recombinases can be altered to recognize target-like sequences using directed evolution
approaches that include a combination o f several techniques: DNA shuffling, PCR
mutagenesis and error prone PCR. The quest to generate variants o f tyrosine
recombinases with desired target specificity began when several mutant and chimeric X
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integrase variants were shown to recombine target sites for HK.022 integrase [4,5]. The
research was boosted by the advances in two molecular evolution techniques: error-prone
PCR and DNA shuffling which allow for the fast generation o f recombinase variant
libraries [6-8]. The solved structures o f the CrdloxP and Flp/FRT complexes [7,8]
provided another boost: they helped utilize another molecular evolution technique, sitedirected mutagenesis o f amino acids that can affect DNA binding so that they can bind to
the target-like sequences efficiently.
For this project, I will focus on two o f the approximately 600,000 recombinase
target-like sequences. One of the target-like sequences (FL-IL10A) is located in the
interleukin gene on chromosome 1 (Figure 1.1). The second target-like sequence (LL69058) is located in the beta-globin gene on chromosome 11 (Figure 1.2). These target
like sequences resemble the FRT and loxP sequences, respectively. The long term goal o f
my project is to evolve and test the Flp and Cre recombinase variants specific for these
target-like sequences.

FL-EL10A

chromosome 1

AA

______

IL10 gene

Figure 1.1: Relative location of the FL-1L10A sequence.
Glu to Val
GAG to GTG
LLi

FL 71362

chromosom e 11

_ /\Z X
HBB gene

Figure 1.2: Relative locations of LL-69058, FL-71362 and E6V (Glu to Val)
mutation.
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1.2 Objectives
The objectives for my research project are as follows:
1. Test variants o f Flp recombinase that can target FRT-like sequence FL-IL10A
from the human interleukin (IL10) gene in mammalian cells (Figure 1.1).
2. Evolve and test variants o f Cre recombinase that can target loxPAike sequence
LL-69058 from the human beta globin (HBB) gene in mammalian cells (Figure 1.2).

1.3 Hypotheses
1. Flp recombinase variants functionally tested in E.coli can integrate a vector
into FL-IL10A in mammalian cells. (Figure 1.1)
2. Cre recombinase variants can be evolved in E.coli to recognize LL-69058 and
functionally tested in mammalian cells to replace a gene cassette when paired with
evolved Flp recombinase variants specific to FL-71362. (Figure 1.2)

1.4 Literature Review
1.4.1 Conservative Site Specific Recombination
and Types of Recombinases
Site-specific recombinases are actively used in mammalian cells to engineer genes
and chromosomes. These recombinases can delete, insert, or invert a gene cassette
flanked by the recombinase target sequences resulting in activating or silencing the gene
cassette [11].
Site-specific recombination leads to DNA rearrangement at specific sequences
called the recombination target (RT) sequences [12]. "Conservative" site-specific
recombination means that there is no loss or addition o f nucleotides at the time o f DNA
rearrangement [13]. Recombinases were discovered in bacteria, temperate phages, and

5
yeast where they exist to perform various events like resolution, inversion and
integration. Conservative site specific recombination was discovered by Allan Campbell
in 1968 during his studies o f bacteriophage lambda and its host bacterium E.coli [14].
Site-specific recombinases function on the principle o f strand breakage and
rejoining and the recombination is divided into several steps. In general, the recombinase
catalyzes cleavage, strand exchange, and rejoining o f the DNA within the synaptic
complex to obtain recombined products [4], The recombinase binds to the two
recombinase target sequences forming a synaptic complex. The core target sequence
consists o f two inverted repeat sequences flanking a spacer or crossover region [15].
Depending on the recombination mechanism, the requirement for accessory proteins,
recognition o f target sequence and strand exchange at the target sequences, recombinases
are divided into two families: serine (Resolvases/Invertases) and tyrosine (Integrases)
recombinases [2,9,13] (Table 1.1).

6

Table 1.1: Examples of recombinases from serine and tyrosine family and their
biological functions [2,9,12-14].

Tyrosine Recombinase
X-Integrases
XerC/D
Flp
Cre
I nt i
XisA/XisC
FimB, FimE
Int of Tn916/Tn 1545

Biological Function
Integration and excision
Excision and resolution
Inversion and resolution
Excision
Integration and excision
Excision
Inversion
Integration and excision

Serine Recombinase
Resolvase

Invertase

Integrase

Some recombinases belonging to the Invertase and Integrase family have
accessory binding sites for expression o f enhancer elements away from crossover regions
(synapse) [17]. The orientation o f target sequences and the location o f the enhancer
sequences for some recombinases are shown in Figure 1.3.
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S ite

P r o te in

FRT

Flp

loxP

Cre

attB

Int
A

Int

- 0 - 0
glx,hlx
res

G in, Hin

0^0

¥4

K

Resolvase

Figure 1.3: Target sequences for conservative site-specific recombinase families.
The brown rectangular box represents the binding target sequence and the inverted
arrows represent the orientation of the target sequence. The circle (A) represent the
accessory site away from the target sequence express the enhancer elements [14].

1.4.1.1

Serine Recombinase Family. Serine residues play a major role as a

conserved amino acid that attacks the DNA and covalently links to the DNA during
strand exchange. The Serine recombinase family is sub-divided into groups based on
performance o f different recombination events like resolution, inversion, and integration.
The major groups o f this family are Resolvases (Tn3, y8), Invertases (Hin, Gin, Cin), and
Integrases (<j>C31) (Table 1.1). The Tn3 resolvase, mobile genetic elements called
transposons found in prokaryotes, require two 28 bp res sequence in direct repeat and six
resolvase dimers to form a fully active synapse. The <j)C31 integrases interact with DNA
attachment sequences called phage attP and bacterial attB sequences to give recombinant
products. These attachment sites favor the integration o f phage genome into the E.coli
genome forming hybrid attL and attR attachment sites. The attP and attB sequences are
39 bp and 34 bp in length, respectively. Evolved <|>C31 integrases are often used as a tool
to manipulate the human genome [2]. When <|>C31 are linked to zinc finger nucleases,
they exhibit rapid genome engineering strategies to recombine at specific loci in the
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human cells or non-human origin cells [18]. The invertase recombinases like the Gin that
recognize gix, Hin that recognize hix (Figure 1.4) require invert repeats o f sequence to
give recombinant products.
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Figure 1.4: Serine recombinase target sequence for invertase family indicating
location of accessory sites that express enhancer proteins (A) and target sequence of
Hin recombinase (B). The inverted arrows show the orientation of hix target
sequence [1].

The Ser residue located in the catalytic domain o f serine recombinase cleaves the
phosphodiester bond o f DNA on all four strands producing a 3'-hyroxyl end and 5'phosphoserine linkage ends as intermediate products [10,15]. In the process o f strand
exchange a structural complex called a synapse is formed. The enzyme-DNA complex is
rotated and ligated to obtain recombines DNA (Figure 1.5).
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Serine recombinases

Figure 1.5: Schematic representation of strand exchange mediated by serine
recombinase [19].

This conserved region contributes to the active site o f the recombinase. The Crotated and ligated to obtain recombined DNA (Figure 1.5). terminal helix-tum-helix
(HTH) domain o f serine recombinases contain highly conserved residues. The N-terminal
catalytic domain consists o f at least 10 highly conserved residues including three cysteine
and non-conserved residues rich in leucine/isoleucine/valine/methionine [1]. The
conserved residues o f invertase family Hin recombinase (which are Fis dependent) are
G lnl51, A rgl54 and Leul55, which directly or indirectly interact with Fis. Any mutation
in the residues can inactivate Hin. y8 resolvase has conserved residues at positions Lys54
and Glu56 which participate in protein-protein interaction between cut DNA strands
(Figure 1.6) [17].
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Figure 1.6: Sequence alignment of DNA Binding Domains of helix a l and helix aB
region of invertases and resolvases members belonging to the serine recombinase
family [17]. The number at the start o f the sequence indicates the position of the
first residue and so on. The red rectangular box indicates the important conserved
residues.

The synaptic complex for serine recombinase forms only when the DNA is
negatively supercoiled. The invertase group o f serine recombinase requires accessory
proteins for their activity. The Fis/enhancer system acts as accessory proteins and
controls the DNA cleavage and exchange [17]. The system is encoded by a sequence
region called an accessory sequence located away from the crossover sequence [15,17]
(Figure 1.5).
Zinc finger nucleases (ZFN) and TALE DNA-binding domains can be adapted to
recognize genomic target sequences. By engineering the ZFN and TALE binding
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specificity and reducing or altering the residue in the serine recombinase structure to
recognize the genomic target sequences it can help increase the application o f evolved
recombinases.
1.4.1.2

Tyrosine Recombinase Family. Tyrosine recombinase families are called so

because the tyrosine residue plays a major role as a conserved amino acid that attacks the
DNA and covalently links to the DNA during strand exchange. The tyrosine residue
attacks the phosphodiester bond on DNA producing 3' phosphotyrosyl intermediate.
Some members o f the tyrosine family include Flp, Cre, ^-Integrase, Xerc/D and Int I
(Table 1.1). They can perform recombination events such as excision, integration,
resolution and replacement.
Other examples o f tyrosine recombinase family members are Int recombinase
which recognizes the attP and attB site, Cre recombinase that recognizes the loxP site,
and Flp recombinase that recognizes the FRT site [11,20]. Figure 1.10 indicates the target
sequences loxP and FRT for Cre and Flp recombinases. The target sequences for
recombinases are composed o f 6-8 bp spacer regions flanked on either side by 13-14 bp
inverted repeats [3,11,20-22]. Change in the bases o f the target sequence can render the
recombinase incapable o f recognizing it [11,20,22].
Tyrosine recombinase binds to the target sequence (bringing sites together)
resulting in a highly structured complex called a synapse. In the complex, a pair o f strand
exchanges occurs which proceed to an intermediate called a Holliday junction
(Figure 1.7).
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Tyrosine recombinases

yg y^jl
exchange

exchange
second pair

Holliday intermediate

Figure 1.7: Schematic representation of strand exchange mediated by tyrosine
recombinase [19].

The Holliday junction is resolved when the second pair strand exchange occurs
forming recombined products [10,23,24], Tyrosine recombinase on cleaving the DNA
strand, produces a 5'-hydroxyl end and 3'-phosphotyrosine ends [10,24,25]. For
tyrosinerecombinase, there should always be sequence homology at the spacer region/
crossover region for recombination to occur. The catalytic domain o f tyrosine
recombinase has four conserved residues located at the C-terminal o f the protein (ArgHis-X-X-Arg-Tyr) and form the RHR traid (A rgl91, His305 and Arg308) in Flp
[10,12,21,25,26], (Figure 1.8). The RHR triad is responsible for the orientation o f the
phosphodiester bonds in the recombination steps [12,26].
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Figure 1.8: Conserved residues of Flp and Cre recombinase in the C-terminal
domain. The tyrosine residing at position 343 in Flp and 324 in Cre in the
catalytic site play a vital role in DNA cleavage [27],

Depending on the location and relative orientation o f their targets, tyrosine
recombinase variants can mediate insertions, deletions, replacements and translocations
o f DNA fragments. Moreover, site-specific recombinases were shown to perform genetic
rearrangements in all cell types tested, from bacteria to plant to human [28,29],
Integration and excision are reversible processes where target sequences are located
on different DNA strands. In Figure 1.9.A, the circular molecule can integrate into the
genome and can be excised from the genome. Resolution yields a circular DNA
plasmid into two small circular molecules. Two target sequences are located on the
plasmid in the same orientation (Figure 1.9.B). In the inversion reaction, the two
oppositely oriented target sequences flip the region between them (Figure 1.9.C). In MCE,
or replacement, the gene cassette is exchanged between two genomes or chromosomes in
(Figure 1.9.D)

14

Exdsioi

y

Inversion

^

7

^

T

Integration

Resolution

Q

RM CE

R
Figure 1.9: Different types of recombination reactions catalyzed by recombinases.
A.) Excision and insertion of DNA in the genome at site-specific target sequence.
B.) A circular DNA molecules resolving in two small circular DNA molecules by
recombining at the target sites. C.) Inversion of DNA occurs when the target
sequences are present in opposite directions. D.) RMCE (Recombinase Mediated
Cassette Exchange) causes replacement of gene cassette which is flanked on either
side with target sequences on two DNA strands.

1.4.1.2.A Cre Recombinase. Cre (cyclization recombinase) recombinases from the
bacteriophage PI were used for the first time in mammalian cells by Sauer in 1989 [30].
Cre recombinases perform two functions, circularization o f linear DNA via the crossing
over loxP, and resolution o f dimers [20]. This recombinase does not require any
accessory proteins and can perform recombination independently [23,31]. Cre
recombinases bind specifically and efficiently at specific target sequences called loxP
sites (Figure 1.10).
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Figure 1.10: loxP and FRT target sequence with 6bp and 8bp spacer flanked with
13-14 bp invert repeats respectively. The inverted arrows indicate the inverted
repeats with spacer region located between them. The small arrows point at the
region of crossing over when recombinase binds to the inverted repeats. The
numbers above the big arrows indicate the location of the bases that vary from
13-14 bp.

1.4.1.2.B Flp Recombinase. Flp recombinase is encoded in the 2pm plasmid o f the
yeast Saccharomyces cerevisiae and recognizes a specific target sequence called FRT
(Flp Recombination Target) (Figure 1.9). Evans et al, in 1990, discovered that the
tyrosine residue at position 343 in the Flp is responsible for its catalytic function but does
not help in substrate recognition [32]. In yeast, Flp recombinases are responsible for
preserving a high plasmid copy number [20].
Cre and Flp tyrosine recombinases have been widely used as tools for genome
engineering. When these recombinases are evolved using directed evolution techniques to
recognize the target sequences, it opens many new areas o f genome manipulation to cure
various diseases. The activity o f the recombinases can be enhanced further by fusing
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them to DNA binding domains o f zinc-finger nucleases and TALE. CR1SPR technology
has also been utilized to guide the delivery o f particular genes to desired destinations in
the genome.

1.4.2 Evolution of Cre and Flp Tyrosine Recombinase Using
Directed Evolution Techniques
In nature, living organisms undergo strict condition constraints that force them to
evolve at the DNA level by inducing mutations in their structure. These mutations can be
beneficial or harmful based on the survival o f the organism. It takes several generations
for the beneficial mutations to express in their genome. This phenomenon o f introducing
mutations can be applied in the laboratory and be used to enhance the property o f a
particular protein, which can result in improving the yield, or increasing the efficiency of
an enzyme or particular pathway. DNA mutagenesis and DNA shuffling are the mostly
widely used laboratory techniques for evolving a particular protein.
DNA mutagenesis can be performed in two different ways, depending on the
knowledge o f the protein structure. They are classified as random evolution technique
and targeted evolution technique.
1.4.2.1 Random Evolution
1.4.2.1.1 Error-prone PCR. Error prone PCR or PCR mutagenesis was first
discovered by Leung, et al in 1989 [33], The protocol was modified by Cadwell and
Joyce in 1992 [34], Random mutations were introduced in the gene fragment by altering
regular PCR conditions (Figure 1.11).
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Figure 1.11: Diagrammatic representation of Cyclic Mutagenesis or Error Prone
PCR, causing introduction of random mutations.

The parameters altered in the reaction include: (1) increasing the concentration o f
Taq polymerase; (2) increasing extension time; (3) increasing concentration o f MgCl2+;
(4) addition o f 0.5mM MnCl2+ and (5) increasing ImM concentration o f GTP, CTP, TTP
and 0.2mM ATP. Parameters o f steps 4 and 5 have higher chances o f introducing random
mutation. The goal behind altering the PCR reaction parameter was to reduce the fidelity
o f amplifying the gene fragment [33].
1.4.2.1.2

DNA Shuffling. DNA shuffling, an evolution technique, randomly

introduces mutations (insertion, deletion, or change in the codon) in the protein structure.
Stemmer was the first to discover the technique o f DNA shuffling, where he began with
shuffling the LacZ gene to observe changes in the P-lactamase pathway [8]. The
procedure, as shown in Figure 1.12, involves shuffling o f two or more homologus genes
with different mutations or allele genes. The genes are digested with DNAse, resulting
into fragmentation o f the genes. Overlapping ends are produced upon digestion as
DNAse makes random cuts in the gene. Small fragments o f the digested gene are
observed on the gel. The gene fragments are assembled in a PCR reaction to reform the
original gene.

18
The overlapping ends act as primers to anneal the fragments together. During this
PCR, in the absence o f a primer, random mutations are introduced into the gene
fragment. The last step involves the use o f specific forward and reverse primers to
amplify the whole gene. The PCR mix is a library o f different recombined genes having
different mutations. The mutations are usually additive enhancing the property o f the
protein or enzyme. Screening o f the gene pool for their activity can help in narrowing
down to the best possible variant which has much better activity than the original genes
used for shuffling [8].
D N ase
Gene 1

•

Gene 2

------- r -

•

Digestion at random
sitesleading to small
fragments

\ I

The two gene fragments are
mixed and amplified using
specific primers

Recombinant genes

DNA Shuffling

Figure 1.12: General overview of DNA shuffling

Zhao and Arnold, in 1997, came up with various modifications for DNA shuffling
that focused on controlling the number o f mutations introduced in the shuffling process.
The rate of mutagenesis was controlled by manipulating the concentration o f DNA
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polymerase, Mg

74-

and Mn

7+

in the PCR reactions. This approach was thought to have a

higher impact on the evolution o f proteins and understanding the evolutionary related
genes [9].
1.4.2.2

Targeted Evolution - Site-Directed Mutagenesis. The main goal o f site

directed mutagenesis is to introduce a single mutation at a particular site in the gene using
mutagenic primers under regular PCR conditions. The goal is to obtain a single mutation,
either a point mutation, deletion or insertion, with a minimum number o f PCR cycles.
Mutagenesis using mismatched oligonucleotides is currently being used in research to
construct mutants. Other methods include mutagenesis using single stranded vectors,
mutagenesis using double stranded vectors and mutagenesis by total chemical synthesis,
as shown in Figure 1.13 [35],

Site-specific m u tatio n s in tro 
duced a t a p a rtic u la r location in
t h f gene

G ene pool
P C R cycles

l

*

l

111i

a
= point mutation
Site-specific M utagenesis PCR
Figure 1.13: Diagrammatic representation of mutation introduced due to site
directed mutagenesis.

The basic operations performed in the method with mutagenic oligonucleotides
involves using primers that have the mutagenic site either on one or both primers. The
primers should anneal at the 5' end o f the mutagenic sites and should be able to amplify
the whole plasmid. Regular PCR conditions are set to allow the primers to anneal at the
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required site with a minimum number o f cycles. Once the PCR product is obtained, it is
treated with Dpnl to get rid o f the parent strand and transformed through the E. coli.
Plasmids obtained are confirmed through sequencing for the desired mutation [36].
1.4.3 Enhancing the Efficiency of Evolved Cre and
Flp Recombinase Variants
To enhance the efficiency o f evolved Cre and Flp recombinase variants, the
recombinase can be fused to DNA binding domains o f the Zinc-finger (ZF) module and
TALE (transcription activator-like effector) module. These modules were designed to
have specificity in binding to the DNA because o f their DNA binding domain. Similarly,
CRISPR protein is another tool used in genome engineering for expanding the targeting
efficiency o f the recombinases.
The ZFR (Zinc Finger Recombinases) perform the recombination autonomously
and do not activate the DNA response pathway [18]. But the short-comings in using zincfinger proteins are that they are limited only to the 64 possible triplet codon combinations
[37], Furthermore, constructing zinc-finger proteins specific to certain DNA sequences is
time consuming and labor intensive [42]. They perform integration with low specificity
and can bind to off-target sequences and thus increase the risk o f having higher rates o f
failure [38]. Due to these drawbacks, ZFR was replaced by more accurate technology like
TALE and CRISPR.
CRISPR was used as an immune defense against invading DNA from
bacteriophage viruses in many diverse bacteria and archaea groups [39,40]. This is the
most recent addition in genome modification and genome engineering, where Cas9
activity is based on the RNA-guided DNA endonuclease [40-42]. CRISPRs are used as a
defense mechanism in bacteria and archaea against exogenous DNA. They are a fusion o f
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CRISPR RNA (crRNA) and CRISPR associated (Cas) protein that together direct the
degradation o f double strand DNA [40]. The double stranded breaks in the DNA due to
Cas9 protein activate the non-homologus end joining (NHEJ) or the homology- directed
(HDR) DNA repair pathway [42,43].
The nuclease in the Zinc-finger Nucleases (ZFN) and TALE nucleases can be
substituted with site-specific recombinase [43], keeping the DNA binding domain and its
function as it is, such that the recombinase can bind to the target sequence, and the DNA
binding domain can be designed to bind to the DNA sequences upstream and downstream
of the target site. DNA binding domains fused with recombinase can help in enhancing
the efficiency o f the recombinase by enhancing the interaction with their respective target
recombination sequence. Discussed below are, in detail, the TALE DNA binding
domains used to manipulate the genomic DNA. My project focuses on the use and
optimization o f TALE DNA binding domain linked to Cre recombinase to recognize the
LL-69058 DNA sequences upstream o f the beta globin gene.
1.4.3.1

TALE DNA-binding Domain. Transcription activator like effector

(TALE) proteins provide an alternative for zinc finger recombinases. Advantages of
using TALE proteins over ZFRs include greater DNA binding specificity, ease of
engineering TALE DNA binding domains, and low toxicity and high cleavage activity
when combined with recombinase [18,19], TALEs are naturally occurring DNA-binding
domains derived from the plant bacterial pathogen Xanthomonas spp. and Ralstonia
solanacearum [18,20,21]. The TALE proteins were used to modulate gene transcription
in host plants to facilitate bacterial colonization where the proteins are delivered to the
nucleus and then to a specific promoter sequence to activate gene expression [35,37].
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Generally, the DNA binding domain consists o f 33-35 amino acid repeat modules
that can be rearranged to bind to a new target DNA sequence [33,35,36]. Each DNA base
(A, C, T and G) is encoded by repeat-variable di-residues (RVD's) called NI, HD, NG
and NN respectively. The 'NI' RVD codes for 'A' DNA base, 'HD' for 'C \ 'NG' for T and
'NN' for 'G' DNA base. In Figure 1.14 below, the di-residues can be used to engineer the
TALE DNA binding domain for any given sequence [38,39], The TALE binding domain
is similar to the ZF binding domains, but the specificity to bind to each nucleotide in the
sequence in higher and it can be engineered to bind to any target sequence, makes the
TALE's preferred over ZF's [47].
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Figure 1.14: Coding pattern for each nucleotide base and engineering TALE DNA
binding domain for a particular DNA sequence with the di-residue repeats.

In my studies, TAL (TALE) plays an important role in binding upstream and
downstream o f the LL-69058 target sequence, allowing the recombinase to bind
specifically to the recombination target sequence. The protein in the TAL's is
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recombinase, Flp or Cre, which acts as the catalytic domain, and the TAL module, which
acts as the DNA binding domain. As shown in Figure 1.15, the TAL DNA binding
domain was engineered to bind to the sequence upstream o f the LL-69058 target
sequence, making it feasible for the evolved Cre recombinase to identify and bind with
higher efficiency to its respective target site. Similarly, TAL can be engineered for
another DNA sequence, where recombination activity is to be performed, thus improving
the probability o f having site-specific recombination rather than random recombination in
the genome with other partially similar target sequences.

Left TAL DNA
binding domain

C rf
variant

genomic DNA
Lett TAL
Target Site

LL-69058

Right TAL
Target Site

HBB Gene

Figure 1.15: TAL DNA-binding domain designed to recognized the left TAL target
site present upstream of the LL-69058 target sequence in the human beta globin
(HBB) gene. The evolved Cre variants are attached to the TAL DNA binding
domain proteins via a linker region.
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1.5 Using Evolved Cre and Flp Recombinase to Recognize
Genomic LL and FL Target Sequence
The human genome has native recombinase target-like sites about every 5kb [5].
These genomic target-like sequences (LL and FL) are not similar to the loxP and FRT
sequences in certain locations (Figure 1.16), but they can be utilized for recombination
reactions by introducing or deleting certain DNA bases from the recombinase gene. The
modification o f these recombinases can be achieved using evolution techniques like DNA
shuffling, PCR mutagenesis and error prone PCR. The modified or evolved Cre and Flp
recombinases can be used to test if they can recognize genomic LL and FL sequences.
The applications o f using site-specific tyrosine recombinases to modify the human
genome are very wide spread and are utilized in gene therapy, gene targeting, and curing
certain diseases [49]. When the recombinases are fused with TAL DNA-binding domain
it helps in further increasing the efficiency o f recombinases to bind at desired target
sequences. Initially, when recombinase enzymes were discovered, gene knock outs were
performed in mice after flanking the gene o f interest with loxP target sequence. Using
TAL-recombinase fusion will be a useful approach as it would act as a good gene therapy
technique for eradication o f many diseases. My project focuses on the potential cure for
genetic diseases. Native recombination target sequences, loxP-like (LL) and FRT-like
(FL) sequences, as discussed above, are utilized to perform integration and replacement
recombination events. I believe that by using TAL DNA-binding domain fused to
tyrosine recombinase, the efficiency o f recombinase will be enhanced and my goal of
attempting to find a potential remedy for replacing the mutated beta-globin gene with a
healthy gene cassette can be accomplished.
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Figure 1.16: Comparison of FRT and FL-IL10A target sequence for evolved Flp
recombinase (A) and loxP and LL-69058 target sequence for evolved Cre
recombinase (B). The green color in the FL-IL10A and LL-69058 target sequences
indicate similar bases to FRT and loxP target sequences, while red color indicates
differences in the bases compared to FRT and loxP target sequence.

CHAPTER 2

METHODS

2.1 Objective 1 - Testing FL-IL10A Integration Using Evolved
Flp Recombinase
2.1.1 Cell Lines and Transfection
Human embryonic kidney HEK 293 cells (ATCC, CRL-1573) were used as model
mammalian cells and native genomic platform cells. The cells were propagated in
DMEM medium. Cell transfections were performed using Polyfect (Qiagen).
2.1.2 Vectors
The reporter vectors for the integration experiments were based on the pcTD vector
that is described in Anderson et al [50], The platform reporter pCMV-ILlOA-DsRed-neo
and the incoming reporter pIL10A-puro-2A-EGFP, which were used in the integration
experiments in HEK 293 cells, were generated as follows. The DsRed-neoR cassette from
pIRES2-DsRed-Express (Clontech) was PCR amplified and subcloned into pcTD
downstream from the CMV promoter to obtain pCMV-ILlOA-DsRed-neo. FL-ILI0A
upstream o f the DsRed-neoR cassette was introduced during the amplification o f the
cassette. The puroR gene from pCAGGS-Flpe-puro (Addgene plasmid 20733) and the
EGFP gene from pIRES2-EGFP (Clontech) were PCR-assembled into one gene through
the connecting 2A peptide and cloned into pcTD downstream from the CMV promoter to
obtain pCMV-IL10A-puro-2A-EGFP. FRT/FL-IL10A upstream o f the puro-2A-EGFP
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gene was introduced during its amplification. The CMV promoter in this plasmid was
then deleted to obtain pIL10A-puro-2A-EGFP.
For the experiments with the intact HEK 293 cells, the pCMV-IL10A-puro-2AEGFP reporter was modified by cloning the PGK promoter from pDIRE25 (Addgene
plasmid 26745) upstream o f the promoterless hygroR gene. To express Flp variants in
mammalian cells, the respective genes were subcloned into pOG44 (Invitrogen) in place
of the Flp-F70L variant gene as described in Anderson et al [50] (Figure 2.1).

pOGlOO

PC'MY.
/ Flp variant'
Nhel

BamHI

Figure 2.1: Expression vector pOG44. The Flp variant is cloned between Nhel and
BamHI restriction sites.

2.1.3 Construction of Platform Reporter Cell Lines
HEK 293-IL10A-DsRed-neo cell line was constructed by transfecting HEK 293 cells
with pCMV-ILlOA-DsRed-neo, propagating them in medium supplemented with
neomycin (800 mg/1) and selecting for the red colonies. Several such colonies were
expanded and tested for singly integrated platform reporter vector by Southern blotting;
the positive colonies were used in the integration experiments.
2.1.4 Integration Experiments
The analysis o f the integration o f the reporters into the respective genomic platform
reporters was performed in the same general way for all three reporter pairs. The
integration reaction was done in 6-well plates. The incoming reporters (0.5 pg) were co
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transfected into the respective platform reporter cells with the vectors that express Flp
variants analyzed. Forty eight hours post transfection, 1/6 o f the cells were transferred
into 100 mm plates, the cells were allowed to become confluent, and the number o f the
green colonies was counted. Several integration positive colonies from these plates were
expanded and analyzed.
The analysis o f the integration o f modified incoming reporter with the
hygromycin gene was tested in the native genomic platform. The transfection was
performed in a 24-well plate. Forty eight hours post transfection, 1/4 o f the cells were
transferred into a 6-well plate. The cells were allowed to settle in the plate for 24 hours
and then the medium was changed to hygromycin containing medium (500 pg/ml). The
hygromycin medium was changed every two days in ten consecutive days until colonies
were formed. The green and non-colored colonies were counted and the positive green
colonies were expanded and analyzed.
2.1.5 Southern Blotting
Approximately 15 pg o f genomic DNA isolated from HEK 293 cells were digested
by SacI overnight followed by incubation with RNase A at 37° C for 1 hr. The digested
DNA was then heat treated at 65°C for 5 min followed by cooling on ice for 5 min. The
DNA fragments were separated on 0.7% TAE agarose (molecular biology grade,
BioRad). The gel was then treated with the depurination solution (0.25M HC1) for 15 min
followed by the alkaline denaturing solution (two times for 30 min). The DNA fragments
isolated from the gel were transferred to the positively charged nylon membrane
(Amersham Hybond-N+, GE Healthcare) in the neutral transfer buffer (20X SSC, GBiosciences). The membrane was then baked at 80°C for 40 min followed by UV
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treatment (5,000 microjoules). Next, the membrane was pre-hybridized in the
ULTRAhyb hybridization buffer (Ambion) at 55°C for 30 min and then hybridized with
the biotinylated EGFP probe (~ 1 pg) at 55°C overnight. The DNA bands were visualized
using the Phototope-Star Detection Kit (New England Biolabs) according to the
manufacturer’s protocol.
2.1.6 Other Methods
Plasmid DNA was isolated using GeneJET Plasmid Miniprep Kit (Thermo).
Amplification o f the DNA fragments used for cloning was performed using Pfu-Ultra
polymerase (Agilent Technologies). PCR analysis o f the mammalian genomic DNA was
performed using Taq polymerase (New England Biolabs). Genomic DNA from cultured
mammalian cells was isolated using GeneJET Genomic DNA Purification Kit (Thermo).
General genetic engineering experiments were performed as described in Sambrook and
Russell [51].

2.2 Objective 2 - Evolution and Testing of Cre Recombinase to Recognize
LL-69058 Target Sequence
2.2.1 Bacterial Experiments
The E.coli strain NEB 10-beta [araD139A(ara-leu)7697 fhuA lacX74 galK
(<|)80A(lacZ)M15) mcrA galU recAl endAl nupG rpsL (StrR) A(mrr-hsdRMS-mcrBC)]
from New England Biolabs was used in all bacterial experiments. The deletion assays in
E. coli were performed essentially as described in Voziyanov et al [10].
2.2.2 Cell Lines and Transfection
Chinese Hamster Ovary (CHO-TD1) cells were used as model mammalian cells.
The CHO-TD1 cell line was constructed as described by Anderson et al [50] and are
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derivatives from CHO Flp-In cells (Invitrogen). Human embryonic kidney HEK 293
(ATCC, CRL-1573) cells were used as wild type mammalian cells. The CHO-TD1 and
HEK 293 cells were propagated in F-12K and EMEM/DMEM medium (Cellgro)
respectively. Cell transfections were performed using DNA-In (MTI globoSTEM).
2.2.3 Oligonucleotides - Site-directed Mutagenesis
Mutagenic primers were designed to introduce particular mutations in the iCre
recombinase gene. The list o f various primers used and their positions are listed in the
Table 2.1. The entire plasmid unwinds and was amplified with the forward and reverse
primers in the presence o f high fidelity polymerase Pfu (Aligent). The linear PCR product
was then run on 1.5% agarose gel and treated with Dpnl (New England Lab) ensuring
degradation o f the parent plasmid. The PCR mixture was then transformed through the
competent E.coli cells and the circular form o f the plasmid was regained on plasmid
isolation. The plasmids were sequenced to confirm the desired mutation.
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Table 2.1: Forward and reverse primer sequences for introducing various sitedirected mutations in the Cre recombinase gene.
T argeted
Site-directed
mutation
position for
iCre
recombinase

Forward Primer

Reverse Primer

M ethionine
24

5'G G A T G C C A C C T C T G A T G A A G T C A IG A
AG
A A C C T G A T G G A C A T G T T C A G G -3'

5'CCTGAACATGTCCATCAGGTTCTTCA
T
G A C T T C A T C A G A G G T G G C A T C C -3'

V aline 24

5’G G A TG C CAC CTCTG ATG AA G TCG IG AA
G
AACCTGATGGACATGTTCAGG-3'

5'CCT G A AC ATGTCC ATC AGGTTCTTC AC
G
ACTTCATCAGAGGTGGCATCC-3'

M eth ion in e 32

5'G A A G A A C C T G A T G G A C A T G T T C A T
GGACAGGCAGGCCTTCTCTGAACAC3’

5'G TGTTC A G AG A A G G C C T G C C T G T C C A
T G A A C A T G T C C A T C A G G T T C T T C -3'

4044

5'G A C A G G C A G G C C T T C T C T G A A N N N
ACCTGGAAGNNNCTCCTGTCTGTGTG
C A G A T C C T G -3’

5'CAGGATCTGCACACAGACAGGAGNN
NC T
TCCAGGTNNNTTCAGAGAAGGCCTG
C C TG TC -3'

24143

5'CCCCAACAACTACCTGTTCTGCCGGG
TC AG A
A A G A A T G G T G T G G C T G C C C C -3’

5’GGGGCAGCCACACCATTCTTTCTGAC
CC
G G C A G A A C A G G T A G T T G T T G G G G -3’

6 972

5 ’-G G A A A T G G T T C C C T G C T G A A C C T
N N N G A TG TG N N N
G A C T A C C T C C T G T A C C T G -3’

5'CAGGTACAGGAGGTAGTCNNNCACA
TC
N N N A G C iT T C A G C A G G G A A C C A T T T C
C-3'

262

5 ’-C C C A A C T G T C C A C C C G G G C C C T G
N N N G G G A TC T T T G A G G C C A C C C A C C 3’

5 ’GGTGGGTGGCCTCAAAGATCCCNNN
CA
G G G C C C G G G T G G A C A G T T G G G -3’

A l ( 25. 29, 32.
33, 35)

5 ’GATGAAGTCAGGAGGAACCTGATGA
GGA
TGTTCGAACTCAGGAGGGCCTTCTCT
G A A C A C -3 ’

5'GTGTTCAGAGAAGGCCCTCCTGAGTT
CGA
ACATCCTCATCAGGTTCCTCCTGACT
TC A TC -3'

A 2 (3 3 7 )

5'GGACTCTGAGACTGGGGCCATGGTG
GAG
C TG C T C G A G G A T G G G G A C -3'

5'G TC C C C A T C C T C G A G C A G C T C C A C C A
TGG
C C C C A G T C T C A G A G T C C -3'
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2.2.4 PCR Mutagenesis (Error prone PCR)
and DNA Shuffling
PCR mutagenesis o f the wild-type recombinase genes and DNA shuffling o f the
variant recombinase genes were performed as described in Bolusani et al [52]. In brief,
mutagenic PCR was performed using Taq polymerase in the Mg-free buffer
supplemented with 0.25 mM MnC12, 0.5 mM MgC12, 200 pM dNTP, 100 nM o f each
primer, and -100 ng o f DNA template. After amplification, the PCR product was
digested with SacI and SphI (iCre recombinase variant gene libraries) and was ligated to
pBAD33 [52] digested with the respective enzymes. To perform DNA shuffling, genes o f
interest were amplified using Taq polymerase under non-mutagenic conditions. The PCR
products were mixed in an equimolar ratio and fragmented with DNase I for 5 min on ice
in the buffer containing 50 mM Tris-HCl (pH 7.4) and 10 mM MnC12. The resultant
DNA fragments were reassembled in the two-step PCR reaction: first, using Pfu-Ultra
polymerase without the addition o f specific primers and then using Taq polymerase with
specific primers that anneal outside the coding region o f the genes. The TAL-Flp libraries
were constructed by my lab colleague, and I tested the functionality o f the Flp libraries
for the FL-71362 target sequence in the bacterial and mammalian cells.
2.2.5 Bacterial Screening Assay
The libraries obtained from site-directed or PCR mutagenesis and DNA shuffling
were required to be screened through the bacterial system to detect potential activity by
the recombinases. The Flp and Cre libraries were cloned in the pBAD33 expression
vector between SacI and SphI restriction sites. These libraries were tested against a
reporter vector p24 which consists o f the hybrid FRT/FL-71362 and loxP/LL-69058 sites
flanking the LacZ gene (Figure 2.2).
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Figure 2.2: Expression p33 and reporter p24 plasmids for bacterial screening assay.

Active libraries recognize the sites and bind to the target site in p24 resulting in
the excision o f the LacZ gene. Both the expression and the reporter vectors were
transformed in the E.coli bacterial strain. These strains were initially made competent
using the p24 reporter plasmid and then used to transform the expression plasmid for
monitoring activity and screening.
2.2.6 Vectors
The reporter vectors for the replacement experiments were based on the pcTD vector
that is described in Anderson et al [50]. The platform reporter p i 372 (EFla-LL-69058neo-STOP-FL-71362-DsRed) and the incoming reporter p i 345 (691oxP/LL-EGFP-CMV71FRT/FL), were used in the replacement experiments in CHO TD-In cells. The platform
p i 372 reporter was created by lab colleague. The incoming pi 345 reporter was generated
by subcloning the EGFP gene from pIRES2-EGFP (Clontech) downstream o f loxP/LL69058 sequence followed by CMV promoter upstream o f FRT/FL-71362 sequence, into
pcTD.
The platform pi 372 reporter and the incoming pi 345 reporter, which were used
in the replacement experiments in CHO TD-In cells, were constructed by modifying the
respective reporters that were used to analyze the dual RMCE reaction by the Flp/Cre
recombinase pair. For this, the neoR-STOP cassette o f the platform reporter was flanked
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by the LL-69058 - FL-71362 sequence while the EGFP-CMV cassette o f the incoming
reporter was flanked by the loxP/LL-69058 - FRT/FL-71362 sequence.
For the experiments in the intact HEK 293 cells, the p979 (691oxP/LL-CMVEGFP -71FRT/FL-EFla-puro-2A-DsRed) incoming reporter was modified by cloning
the inverted PGK promoter from pDIRE (Addgene plasmid 26745) upstream o f the
promoterless hygroR and ployA (from p6350) gene.
2.2.7 Construction of Platform Reporter CHO Cell Line
To construct the CHO TD-( EFla-LL-69058-neo-STOP-FL-71362-DsRed ) cell
line, CHO TD-In cells were co-transfected, in 6-well plates, with the pl372(E Fla-L L 69058-neo-STOP-FL-71362-DsRed) reporter (0.2 pg) and the pOG-TDl-40 vector (2
jig), which express the TD1-40 variant o f TD recombinase. Forty eight hours post
transfection, 1/6 o f the cells were transferred into a 100 mm plate containing F12-K
medium supplemented with hygromycin (550 mg/1). About 10 days later, several
hygromycin resistant, colorless colonies were transferred into a 96-well plate and their
sensitivity to zeocin was tested; zeocin sensitive colonies were expanded and used in the
replacement experiments.
2.2.8 Construction of TAL Recombinases
2.2.8.1

Golden Gate TAL Construction. The DNA-binding domain o f TAL is

built by the assembly o f RVD's for a particular sequence. The sequence upstream and
downstream of the LL-69058 target sequence was used as the DNA-binding domain for
constructing left and right TAL respectively. The protocol for constructing the DNAbinding domain involves the following steps illustrated in Figure 2.3 and 2.4.
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>direct sequence
AGAGAA AGC ATTTA AGAGA AT A A AGC AAT GG AAAT AAG AA ATTTGT AAAT
ttc c tt c tg a t a a c ta g a a a ta g a g g a tc c a g tttcttttggttaac

c ta

AATTTT ATTTC ATTTT ATTGTTTT ATTTT ATTTT ATTTTATTTT ATTTTGT GTA
ATCGTAGTTTCAGAGTGT
>inverse sequence
ACTGGATCCTCTATTTCI AGTTATCAGAAGGAAATTTAC AAA I I 1
O T A T T T C C ATTGCTTTATTCTCTTAAAT GCTTTCTCT ATTATTGCT AAAT A
AATAGAGATCTCTCACTTTTTCTACCTGTCTCAACCCTCATCAGGTACTTG

Figure 2.3: The direct and inverse sequences of the human beta-globin gene near the
LL-69058. The target sequence is shown in green. The DNA binding domain for
TAL downstream direct sequence (right TAL) and upstream inverse sequence (left
TAL) are shown in blue.
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RVD Assembly For Right TAL DNA-binding Domain
A. TAL DNA-binding domain (Right) - 15 nucleotide sequence
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B. TAL DNA-binding domain (Left) -1 5 nucleotide sequence
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Figure 2.4 The construction of TAL DNA binding domain using single RVD's to
clone into pFUSA and pFUSB vectors for the sequence located (downstream) right
(A) and (upstream) left (B) of the LL-69058 target sequence.

A sequence consisting o f 18,15 and 12 nucleotides located upstream and
downstream of the LL-69058 target sequence was selected to construct the TAL
DNA-binding domain. Figures 2.3 and 2.4 indicate the upstream and downstream
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selected sequence and the construction o f the binding domain for 15 nucleotides with
single RVD's.
I. The first step was to assemble 10 nucleotides o f the sequence with their
respective RVD's (Figure 2.4). The assembly o f first ten RVD had to be cloned in the
pFUSA vectors. The remaining nucleotides, 11-14, were assembled and cloned in another
vector called pFUSB4. The last residue (LR) o f the sequence was kept as a single RVD
and was not used in the first round o f assembly. A 20pl PCR mixture consisting o f
pFUSA vector backbone, the first 10 nucleotide RVD, ligase, Bsal, ligase buffer, DTP
and the remaining volume made up with water was prepared. A second 20 pi PCR
mixture consisting o f pFUSB4 vector backbone, remaining 4 nucleotide RVD's, ligase,
Bsal, ligase buffer, DTP and the remaining volume made up with water was prepared.
The PCR mix was incubated in a PCR machine for 20 cycles at 37°C for 15 minutes, 16°C
for 10 minutes and then incubated at 50°C - 15 minutes and 16°C - 15 minutes and then
heated again at 80°C - 20 minutes. After PCR, the mixture was passed through E.coli via
transformation and plated on spectinomycin X-gal media plates. The pFUS vectors
consist o f LacZ appear blue if the RVD's do not assemble in them, otherwise on RVD
assembly the colonies appear white.
II. The white colonies were picked, the plasmid was isolated and sequenced so as
to use the correctly assembled RVD's in pFUSA and pFUSB4 to further clone into the
final pOG-TALE core vectors.
III. The pFUSA, pFUSB4 plasmid and the last residue (LR) were then assembled
in the pOG-TAL core. The TAL core was amplified from the pTAL3 vector using
different N and C terminal primers. The N terminal primers were designed to bind at the
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28, 63 and 75 nucleotide position and the C terminal primers are designed to bind at the
117, 131 and 152 position in the pTAL3 plasmid.
The PCR mixture for final assembly consisted o f pOG-TALE core vector,
pFUSA, pFUSB4 vector, last repeat (LR), ligase, Esp3I, ligase buffer, DTP and the
remaining volume made up with water. The PCR mixture was incubated for 20 cycles at
37°C - 5 minutes and 16°C -1 0 minutes and then heated to 37°C -1 5 minutes, 16°C
minutes and heated again at 80°C - 15 minutes. After PCR, the mixture was passed
through E.coli via transformation and plated on Ampicilin X-gal plates. The pOG-TAL
core has LacZ gene and if the pFUS vectors and last repeat were inserted in the
pOG-TAL core, the colonies appeared white in color.
IV. The white colonies were picked and the plasmids were isolated. The plasmids
were sent for sequencing and the correct plasmids were ready for being used to attach the
Cre recombinase gene.
V. The Cre recombinase was amplified from the various variants mentioned in the
tables above using Cre specific primers with additional sequence at the N terminal. The
additional sequence is called the linker region which gives flexibility to the recombinase
in order to find LL-69058 target sequence. The PCR product was digested with respective
enzymes and cloned in the correctly assembled pOG-TAL core vectors.
2.2.8.2 Optimization of Linker Region Between the
TAL Domain and Recombinase. The linker region that connects the
TAL binding domain and recombinase were adjusted using different lengths o f linkers
called half, one and full (one and half) spacer sequence. The sequence o f the linker
regions are listed in Table 2.2. The linkers were added to the iCre variant using primers.
The iCre gene along with different linker lengths were cloned in pOG vector between
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Nhel and BsrGI restriction sites and in pBAD33 vector between SacI and SphI restriction
sites.

Table 2.2: Linker region sequences for half, one and half and full length. The
underlined sequence indicate the common linker on which the one and half and full
linker are built (Bold).

H alf linker

S'-GTCCCCATCCTCGAGCAGCCTCACC-S’

One linker

5^GCCGCTTCCGCCTGAGCCGTCCCCAfcCTCGAGCAGCCTCACC3'

Full linker

5'TGATGTGCCTGAGCCGCCGCTTCCGCCTGATCCTCCGCTTCC
G TCCCCATCCTCGAGCAGCCTCACC-31

2.2.9 Dual Recombinase-Mediated Cassette Exchange
(RMCE) Experiment in CHO Model Cells
The cassette exchange reaction between the incoming reporter pi 345 (691oxP/LLEGFP-CMV-71FRT/FL) and the platform reporter p i 372 (EFla-LL-69058-neo-STOPFL-71362-DsRed) ( integrated into CHO TD-In) was performed similar to the integration
experiments. The incoming reporter (0.36 pg) and the expression vectors pOG-TAL-Cre
(0.003 pg) and pOG-TAL-Flp (0.02 pg) were co-transfected into CHO T D -l(E Fla-L L 69058-neo-STOP-FL-71362-DsRed) model cell line. Forty eight hours post transfection,
1/16 o f the cells were transferred into 6-well plates, the cells were allowed to become
confluent, and the number o f the green, red, and green/red colonies was counted. Several
green/red colonies from these plates were expanded and analyzed.
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2.2.10 Optimization o f Right and Left pOG-TAL-recombinases
for Efficient Binding in CHO Model Cells
The pOG-TAL-Cre variants were paired based on different lengths o f the TALE
binding domain. Various concentrations o f the left pOG-TAL-Cre recombinase were
paired with the right pOG-TAL-Cre recombinase to analyze maximum attainment of
green/red colonies in the CHO model cells.
2.2.11 Integration of pQG-TAL-Fln and pQG-TAL-Cre
in Wild Type HEK 293
The analysis o f the integration o f the incoming reporters 979 (691oxP/LL-CMVEGFP-inv PGK-hygro-pA-71FRT/FL-EFla-DsRed) into the respective genomic
platform reporters was performed in the same general way for all three reporter pairs
(Left/right TALE recombinases and incoming 979 reporter). The integration reaction was
done in 24-well plates. The incoming reporters (0.45 pg) were co-transfected into the
genomic platform with the vectors that express pOG-TAL-Flp (0.2 pg) variants (0.02 pg
in the replacement experiments in CHO model cells) and pOG-TAL-Cre (0.3 pg) (0.003
pg in the replacement experiment in CHO model cells) in separate wells. Forty eight
hours post transfection, 1/4 o f the cells were transferred into 6-well plates, the cells were
allowed to settle in the well for 24 hours and then the medium was changed to
hygromycin (500 pg/ml). The hygromycin medium was changed every 2 days for 10
consecutive days until colonies were formed. The number o f the green, red, green/red and
non colored colonies was counted. Several integration positive colonies for pOG-TALFlp (just red not green) and pOG-TAL-Cre (just green not red) from these plates were
expanded and analyzed.

CHAPTER 3

RESULTS

3.1 Results for Objective 1: Testing FL-IL10A Integration
Using Evolved Flp Recombinasel531
3.1.1 FV7 is Active in Human Cells
Having established that FV7 is active in the integration and replacement reactions in
CHO cells, we next tested the ability o f FV7 to utilize the FL-IL10A sequence as a
substrate in human cells in a model setting. For this, we integrated an FL-IL10A bearing
platform reporter into human embryonic kidney 293 cells, HEK 293. In the integrated
platform reporter, FL-IL10A is located between the CMV promoter and the DsRed gene
(Figure 3.1 A). In the incoming reporter, the hybrid FRT/FL-IL10A sequence is located
upstream o f the promoterless puro-2A-EGFP gene. Upon integration o f the incoming
reporter into the platform reporter, the expression o f the puro-2A-EGFP gene is activated
so the cells become green and resistant to puromycin.
To test what fraction of the green colonies represent the correct integration o f the
incoming reporter into the platform reporter, we subjected ten green colonies to PCR and
Southern blot analyses. All ten colonies were positive for the integration specific PCR
bands, (Figure 3 .ID), the identity o f which was confirmed by sequencing. The Southern
blot analysis showed that in all but one colony the incoming reporter was singly
integrated into the platform reporter (Figure 3.1).
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Figure 3.1: Flp variants FV7, FV9 and their derivatives can integrate a reporter into
the FL-IL10A site pre-integrated into the human genome. (A) Schematic outline of
the integration assay. The horizontal blue and red bars in panels (A) and (D)
schematically represent the PCR products at the left junction (LJ) and the right
junction (RJ) of the integration product and the control PCR product o f the
platform reporter (C2). (B) Expanded green, puromycin-resistant cells do not
express DsRed. (C) Southern blot analysis of the expanded green, puromycinresistant colonies. The green bar in panels (A) and (C) shows the location of the
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integration-specific DNA fragment. M, biotinylated DNA marker. (D) PCR analyses
of a typical green, puromycin-resistant colony. LJ and C l, the PCR analysis o f the
green cells and the control platform cells using the primers that anneal on the CMV
promoter and the puroR gene. RJ and C2, the PCR analysis of the green cells and
the control platform cells using the primers that anneal on the vector backbone and
the DsRed gene. M, DNA marker. (E) The integration activity of the Flp variants
FV7, FV9, FV7o, and FV9o as a function of the location of the NLS sequence and
the input of the corresponding recombinase expression vectors at transfection. The
results are represented by the data points connected by a line of the respective color.
The data points show the mean value o f five experiments; the error bars indicate
standard deviation.

3.1.2 The Activity of FV7 in Human Cells can be Enhanced
bv ‘Humanizing’ the FV7 Gene and bv
Adding NLS to its Termini
The activity o f FV7 in human cells was low, so we explored two approaches to
increase it: (1) codon optimization o f the FV7 gene to maximize its expression in human
cells; and (2) addition o f the SV40 nuclear localization sequence, NLS, to its N- or Ctermini to facilitate the crossing o f FV7 into the nucleus. These modifications were
successfully applied to increase the activity o f Cre and Flp in mammalian cells [54,55] In
the optimization experiments, in addition to FV7, we used a de novo evolved Flp variant,
FV9, which recombines FL-ILIOA in the bacterial deletion assay slightly better than FV7.
FV9 differs from FV7 at position 166: FV9 has wild-type Lys at this position while FV7
has Glu.
We tested the integration activity o f the original and the modified recombinases at
the different inputs o f the respective expression plasmids. FV7 was able to generate green
cells only at the higher inputs: 4 pg and 0.4 pg o f the expression plasmids per
transfection (Fig. 3.IE, top panel). FV9 was more active than FV7 but it was not able to
generate green cells at the lowest input o f the expression plasmids tested: 0.013 pg
(Figure 3 .IE, top panel). The ‘humanized’ versions o f FV7 and FV9 - FV7o and FV9o -
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had higher integration activity than FV7 and FV9 and were able to generate green cells
even at the lowest input of the expression plasmids (Figure 3. IE, bottom panel). Unlike
FV7 and FV9 that had essentially flat activity at the higher inputs o f the expression
plasmids (4 pg and 0.4 pg), FV7o and FV9o had a pronounced peak o f activity at 0.4 pg.
Although the addition o f NLS to the N- or C-termini o f both non-optimized and
optimized recombinase variants increased their integration activity, this modification was
not powerful enough to allow the not-optimized FV7 and FV9 to generate green cells at
the lowest input o f the expression plasmids (Figure 3. IE, top panel). The variants with
added NLS followed the FV7o and FV9o pattern and had a pronounced peak o f activity
at 0.4 pg o f the respective expression plasmids added at transfection (Figure 3. IE). For
FV7 and FV9, it was the N-terminally placed NLS that helped them to achieve their
highest integration activity. In contrast, the ‘humanized’ FV7o and FV9o benefited more
from the C-terminal NLS. It was FV9o with this modification, FV9o-NLS, which showed
the highest integration activity o f all recombinase variants tested: ~ 0.35% o f the
transfected cells (Figure 3 .IE).
3.1.3 FV9o-NLS Can Target FL-IL10A Located in its
Native Chromosomal Environment.
Finally, we tested the ability o f FV9o-NLS to integrate a reporter into the native
FL-IL10A sequence in the intact HEK293 cells (Figure 3.2). For this, we modified the
targeting vector described in the previous section to include the constitutively expressed
hygromycin B phosphotransferase gene under the control o f the PGK promoter (Figure
3.2A) to help enrich the cell population that bears the integrated targeting vector.
The integration experiments were performed by co-transfecting the targeting
vector and the FV9o-NLS expression vector into HEK293 cells. In the control
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experiments performed in parallel, the HEK293 cells were co-transfected with the
targeting vector and the empty expression vector. Forty-eight hours post transfection, the
cells were expanded in the hygromycin supplemented medium for about a week and the
ratio o f the green to non-green colonies assessed. Then, the cells were collected and
analyzed by PCR and sequencing.
In the control experiments with the empty expression vector, the ratio o f the green
to non-green colonies was 2.08±0.16. In contrast, the ratio o f the green to non-green
colonies in the experiments with FV9o-NLS was significantly lower: 0.62±0.23 (Figure
3.2B). The PCR analyses o f the genomic DNA isolated from the collected cells showed
that the characteristic, integration-specific bands were generated only when the cells were
transfected with the FV9o-NLS expression vector but not with the empty one (Figure
3.2C). Sequencing of the integration-specific bands confirmed the targeting o f the
FL-IL10A sequence (Figure 3.2C).
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Figure 3.2: FV9o-NLS can integrate a reporter into the native FL-IL10A sequence
in the human genome. (A) Schematics of the integration assay. Upon expression of
the FV9o-NLS variant, the incoming reporter can integrate into the native FLIL10A site. Successful integration leads to the loss of the expression of the puro-2AEGFP gene due to the separation from the promoter. (B) Co-transfection of the
reporter and either the empty expression vector or the vector that expresses FV9oNLS leads to the different ratios of green to non-green colonies. The results show the
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mean value of three experiments ± standard deviation. (C) The PCR and sequencing
analyses of the pooled transfected and expanded cells. The analyses were performed
at the left junction (LJ) and the right junction (RJ) of the integrated reporter vector
and the genomic DNA. The blue and green bars in panels (A) and (C) show the
location of the integration specific PCR products. Int, PCR analysis o f the pooled
transfected cells; Ctr, control PCR analysis of the original cells using the same
primers as in lane ‘Int’; M, DNA marker. The FL-IL10A specific snapshots of the
sequencing reads of the integration-positive PCR bands are shown on the right side
of panel (C).
The overall goal o f the above experiments was to test if the FV7 variant could
recognize and integrate gene cassette in the HEK293 cells. FV7 is active in the
mammalian cells. Its activity was enhanced when it was fused to C-terminal NLS
sequence. Also when FV7 was codon optimized and fused to C-terminal NLS there was
35-fold increase in integration activity.

3.2 Results for Objective 2; Evolution and Testing of Cre Recombinase to
Recognize LL-69058 Target Sequence
3.2.1 TAL-Cre Variant is Active in the Bacterial
Deletion System
My first experimental aim was to screen the evolved TAL-Cre variants to monitor
efficient recombination activity at the LL-69058 target sequences in the bacterial deletion
assay system. Evolved TAL-Cre variants (containing M24, V24, M32 mutations in Cre
gene), Table 3.1 were passed via transformation through p24 reporter containing
competent E.coli cells. The LacZ gene in the p24 reporter was flanked on either side with
either LL-69058, loxP or hybrid LL-69058/loxP target sequences. The TAL-Cre variants
were cloned in bacterial pBAD33expression vector. This expression vector containing a
pBAD promoter and Arabinose operon have characteristic control on repression,
induction and expression o f genes cloned into the pBAD vectors [56]. Thus the amount
o f TAL-Cre gene expression was tightly regulated by the Arabinose operon. The more
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the Arabinose in the culture medium, the more active was the Arabinose operon, resulting
in higher production o f TAL-Cre protein.
The assembled TAL core DNA-binding domain used for fusing the Cre variants
was amplified from the pTAL3 vector. Each left and right arm o f the TAL DNA-binding
domain was assembled with RVD's for 18 nucleotides. The primers amplified the binding
core beginning from the 95th position at the N-terminal and from position 117, 131 and
152 at the C-terminal o f the pTAL3 vector. Therefore, the Cre variant was cloned in three
different assembled TAL core DNA-binding domains named TAL 117+95, TALE
131+95 and TALE 152+95, respectively, for initial bacterial screening. The Cre variants
were PCR amplified using half linker region primers in order to fuse the TAL core DNAbinding region and Cre variant.
The different TAL-Cre variants upon being expressed bind to the target sequences
flanking the LacZ gene resulting in the deletion o f the LacZ gene. If the variants can
recognize the target sequence, the colonies on the plate lose their blue color and appear
white. Also the p24 reporter on the gel appears to migrate at a lower level compared to
the original reporter (Figure 3.3), indicating that the TAL-Cre variant is active in the
bacterial system and it deleted the LacZ gene. Various concentrations o f arabinose were
used to monitor high deletion activity in the bacterial cells.

Figure 3.3: Bacterial screening assay showing an agar plate containing chromogenic
substrate X-gal with white and blue colonies (A). Gel image of plasmids isolated
from the white and blue colonies (B). The topmost bands is the pBAD33 expression
plasmids. The lower band indicates the p24 reporter where if the LacZ is deleted the
plasmid migrates lower than the p24 reporter plasmid. Control (Cont) shows
presence o f two plasmids, containing LacZ (upper band and deleted LacZ (lower
band) in the p24 reporter.

The bacterial assay with three different p24 reporter systems indicated some
activity at 0.001% and 0.1% arabinose concentrations (Table 3.1). Out o f the various
TAL-Cre variants passed through the bacterial deletion assay, TAL-Cre variant with a
mutation at position 24 position in the Cre gene showed the highest deletion activity. The
mutation at position 24 causes a change o f amino acid from Arginine to Methionine.
It was observed that the bacterial deletion activity was highest with the pBAD33TAL-117+95-Half linker-Cre-M24 variant. The pBAD33-TAL-l 17+95-Half linker-CreM24 variant showed 0.75% deletion activity (21 white colonies in 2800 colonies) at
0.01% arabinose on genomic LL-69058 target sequence as compared to 0.7% (20
colonies in 2800 colonies) deletion activity at 0.01% arabinose on wild type loxP target
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sequence. Therefore, the pBAD33-TAL-l 17+95-Half linker-Cre-M24 variant could
recognize the genomic target sequence as efficiently at it could recognize the wild type
target sequence. The Cre variants fused to TAL 131+95 and 152+95 showed no deletion
activity in the bacterial assay. In the control experiments, plain Cre-M24 variant (without
fusion to TAL core DNA-binding domain) was passed through the bacterial screening
assay to test the deletion efficiency. There was no deletion activity observed and the
results were unsuccessful.

Table 3.1: The target sequences used in p24 reporter flanking the LacZ gene and the
deletion activity observed under 0.001% and 0.01% of arabinose concentration. The
red highlight indicates the only activity observed in the bacterial assay.

Target sequence in p24 reporter
flanking the LacZ gene
Genomic LL-69058

Arabinose
concentration
0.001%

Deletion activity in
bacterial cells
(2800 colonies/big plate)
0% white colonies

TTTCCTTCTGATAA CTAGAA
ATAGAGGATCCAGT

0.01%

0.75% white colonies, no
semi-blue colonies.

loxP -loxP (Full)

0.001%

ATAACTTCGTATAG CTAGAA
TTATACGAAGTTAT

0.01%

Just 2 white colonies in
2800 colonies, (negligible
activity)
0.7% w hite colonies,
30% semi-blue colonies.
0% white colonies

Genomic-loxP (Half)
TTTCCTTCTGATAA CTAGAA
TTATACGAAGTTAT

0.001%
0.01%

Just 1 white colony in
2800 colonies,
(negligible activity)

Though the deletion activity with pBAD33-TAL-l 17+95-Half linker-Cre-M24
was low in the bacterial system, it still showed significant activity to test the TAL-Cre
variant in the mammalian cells. The active pBAD33-TAL-l 17+95-Half linkerCre-M24
variant was then transferred into pOG expression vector to test the replacement activity in
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mammalian cells. Furthermore, in the next experiments, pOG-TAL-117+95-Half linkerCre-M24 variant will be addressed as TAL-Cre-M24.
3.2.2 Selection O f Active Cre Variants Obtained
Through DNA Shuffling
As the TAL-Cre-M24 variant showed some activity in the bacterial assay, new
Cre libraries were built keeping Cre-M24 as the base template. Table 3.2 below shows
various random mutations introduced in the Cre-M24 gene during DNA-shuffling and
error prone PCR protocols. The Cre libraries were directly cloned in the mammalian
expression vectors to test the replacement efficiency in the model CHO cells. The Cre
variants were also fused to the TALE-core DNA-binding domain to compare the activity
between Cre variants with and without the TAL-core DNA-binding domain. The
experiments with Cre variants not fused to the TAL-core-DNA-binding domain were
unsuccessful and did not give any green/red colonies in the replacement experiments. But
the Cre variants fused to TAL-core DNA-binding domain had few green/red colonies, but
on expansion o f these colonies the green color faded leaving just red colonies. These
results are unexpected and thus the Cre variants cannot be used for the replacement
experiments (Table 3.2).

Table 3.2: Random mutations introduced in Cre recombinase gene using error
prone PCR or DNA shuffling methods.
Variant No.

iCreM24-

Amino Acid

AA

Protein Change

(AA)Change

Position

Position

No.

No.

Protein

l.G A A to AAT

1.808

E to N (Glu to Asn)

262

iCreM24-

l.G A A to AAA

1.223

1. E to K (Glu to Lys)

67

262-14

2. GAC to AAC

2.241

2. D to N (Asp to Asn)

73

3. GAA to AGC

3. 880

3. E to S (Glu to Ser)

262

l.G A A to AGC

1. 880

E to S ( Glu to Ser)

262

iCre ScSh

1. AGG to ATG

1.95

R to M (Arg to Met)

24

9-1

2. AAC to GAC

2. 199

N to D (Asp to Asp)
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3. GAT to AAT

3. 589

D to N (Asp to Asn)

189

4. GTG to GCG

4. 650

V to A (Val to Ala)

209

5. GAA to GGA

5. 809

E to G (Glu to Gly)

262

Loss o f two

1036

Loss o f Leu codon

337

262-1

iCreM24262-21

iCre 6-2

nucleotides-CT

3.2.3 TAL-Cre M24 Can Perform Efficient Replacement
of Gene Cassette in CHO Model Cells
To test if a target-specific TAL-Cre-M24 variant can be combined with another
site-specific recombinase to perform dual recombinase-mediated cassette exchange (dual
RMCE) in mammalian cells, we paired TAL-Cre-M24 with TAL-Flp in a model setting
similar to what we used to analyze the replacement activity o f the Flp/HK022 Int
recombinase pair [29], The TAL-Flp variant was constructed and evolved by another
member o f the lab and I tested and optimized the variant in replacement experiments. For
this, the respective cognate target sequences were introduced for Cre and Flp in the
52
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incoming and platform reporters o f the replacement system (Figure 3.4) and the platform
reporter was then integrated into genome o f CHO cells.
A schematic of the assay to test the replacement activity o f the TAL-CreM24/TAL-Flp recombinase pair is shown in Figure 3.4(A). In the integrated platform
reporter, LL-69058 target sequence is located between the E F la promoter and the neoR
gene while FL-71362 target sequence is located upstream o f the promoterless DsRed
gene. The incoming reporter bears the hybrid loxPILL-69058 site upstream o f the
promoterless EGFP gene whereas FL-71362/FRT is positioned downstream o f the CMV
promoter. If the TAL-CreM24/TAL-Flp recombinase pair is active in the dual RMCE
reaction, the neoR-STOP cassette o f the platform reporter will be replaced with the
EGFP-CMV cassette o f the incoming reporter; this recombination event can be detected
by the activation o f the expression o f both EGFP and DsRed genes in the same cell. The
expression o f just DsRed will indicate the Flp-dependent integration o f the incoming
reporter into the platform reporter at the FL-71362 site while the expression o f just EGFP
will signify the CreM24-dependent integration o f the incoming reporter into the platform
reporter at the LL-69058 site.
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Sequencing result of LJ after replacement in CHO model cells
GCTTGGTACTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGGTAAGCTTGGTACCAGAATAAAGCAAT
GGA AATAAG AAATTTGTAAATTTCCTTCTGATAACTAG AAATAG AGGA TCCA GTT T C T T T T G GTTAACCTAA A
TTTTATTTCA TTCTTC CATCGGCA TAG TA TATCGG CATAG TATAA TACG A CAAG G TGAG G AA CTAAA CCCCTT
TGAAAAACACGATGATAATATGGCCACAACCA TG G TGA GCAAG GGCGA GGAG CTG TTCACCG GGGTGG TGCCC
ATCCTGGTCGAGCTG

Sequencing result of RJ after replacement in CHO model cells
GG TA TG G CATGATAACG CCCGGAA GAGA GTCAATTCAGGG AGATACA TTAA GTA ACTTA AAAA AAAA CTTTAC
ACA GTCTGC C TA G TA C A TTA C TA TTTG G A A TA TA TG TG TG C TT A T T T G C A TA TT C A T A A TC T C C C T A C T T TA T
TTTCTG CTAG CA CCA TGG CCTCCTCCGA G GA CGTCATCA A GGA G TTCATG

Figure 3.4: Dual recoinbinase-mediated cassette exchange, RMCE, mediated by
TAL-Cre-M24 and TAL-Flp variants at relative location of the loxP-Iike sequence
LL69 (LL-69058) and FRT-like sequence FL71 (FL-71362) in the CHO model
genome. (A) Schematic of the dual RMCE reaction to test the replacement activity
of the Cre and Flp variants. The cells, in which the replacement occurred, express
both EGFP and DsRed on efficient replacement. (B) The green/red colony formed
after the active TAL-Cre-M24 and TAL-Flp variants recognize and replace the gene
cassette at the genomic target sequences in model cells. (C) The left and right
junction PCR analysis bands confirm the replacement of gene cassette by the
correct band size of 750bp at left junction and the band size of 700 bp at the right
junction. (D) The sequencing of the PCR bands indicate the genomic LL-69058
sequence at the left junction highlighted in green and the FL-71362 sequence at the
right junction highlighted in red. The blue highlighted regions in the left junction
sequence are the left and right TALE-core DNA-binding domains for TALE-CreM24 variant.

55
To perform the replacement, we co-transfected the platform reporter cells with the
incoming reporter and the vectors that express TAL-Cre-M24 and TAL-Flp. Forty eight
hours post-transfection, the cells were expanded and examined for the colonies that
express either EGFP or DsRed, or both (Figure 3.4A and B). These colonies and not
individual cells that express EGFP and/or DsRed were considered true indicators o f
recombination events. To confirm that the EGFP and DsRed expression in the green/red
colonies reflects the expected reporter replacement, we expanded several such cell groups
and analyzed them by PCR (Figure 3.4C) and sequencing. Approximately 1 or 2
green/red colonies were obtained after every transfection from 25 pi o f cells transferred
in a 6-well plate.
3.2.4 Cre M32 Variant Shows High Recombination Activity
when Fused with Left TAL (15 nucleotide).
Right TAL (12 nucleotide) and Half
Spacer Region
As the number o f green/red colonies obtained in the replacement experiment was
less with the TAL-Cre-M24/TAL-Flp variants, it was necessary to find an alternative
approach to increase the yield o f green/red colonies. The TAL-core DNA-binding
domains were first altered to observe if there was any significant change in the number of
green/red colonies. In the above replacement experiment, the left and right assembled
TAL DNA-binding domains were assembled with RVD's for 18 nucleotides. New TALcore DNA-binding domains were constructed by assembling RVD's for 12 and 15
nucleotides for both left and right arms. The Cre-M24 variant was cloned with a half
linker region in the assembled TAL-core DNA-binding domain. Different combinations
o f left and right arms were optimized by co-transfecting the plasmids in model CHO cells
to observe the replacement efficiency.
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We observed a 5-fold increase in the replacement activity when the combination
o f 12 nucleotide RVD (RV12) assembly and 15 nucleotide RVD (LV15) assembly were
fused with Cre-M24 variant prior to transfection. On average at least five green/red
colonies were observed with every 25 pi transfer o f cells into 6-well plate. The
transfections were performed by co-transfecting these new TAL RV12 and TAL LV15
Cre-M24 variants with TAL-Flp and the incoming reporter. On expansion and PCR
analysis, the PCR produce was o f the correct size and the sequencing confirmed the
replacement o f the gene cassette.
To continue improving efficiency, the linker region fused to the TAL-core DNAbinding domain and Cre-M24 variant was altered. The number o f green/red colonies
observed with one and full linker spacer region between the TAL-core and recombinase
was five times less compared to the original half linker region. This attempt o f altering
the linker region was unsuccessful and the half linker proved to be the better fit for
allowing the Cre variant to recognize the genomic LL-69058 target sequence. Our next
aim was to alter the TAL-core length at the N-terminal. The original TAL-Cre-M24
variant had the combination of 117+95. As 117 at the C-terminal was the only position
that gave activity in the bacterial assay, no alterations were performed at the C-terminal.
New TAL-core plasmids were built with +28 and +63 starting lengths at the N-terminal
that were PCR amplified from the pTAL3 vector. The new TAL-core 117+28 and TALcore 117+63 were assembled with right 12 nucleotide RVD's and left 15 nucleotide
RVD's and later fused with Cre-M24 variant with a half spacer region.
The transfections with 117+95, 117+63 and 117+28 TAL-core left and right
TAL-core DNA-binding domains fused to Cre-M24 variant were performed in the model
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CHO cells along with the incoming reporter and TAL-Flp variant. The replacement
efficiency was calculated based on the number o f green/red colonies observed and it was
noted that 117+95 TAL-core had two times more green/red colonies compared to 117+63
and 117+28 TAL-cores.
Thus the best combination o f TAL-core DNA-binding domain fused to Cre-M24
variant was the TALI 17+95-half spacer-Cre-M24 with left arm o f 15 nucleotides (LV15
and right arm with 12 nucleotide (RV12). In control experiments, Cre-M24 was used in
the replacement experiments, to observe if the recombination efficiency without the TAL
domain attached. There was no significant activity when plain Cre-M24 variant was
added in the experiment. The new version o f TAL-Cre-M24 is addressed as TAL-CreM24 -LV15/RV12. TAL plays a major role in guiding the Cre-M24 variant to recognize
and bind to the genomic target sequence.
3.2.5 Integration in HEK 293 Cells with
TAL-Flp Active Variant
The next goal was to test the ability o f TAL-Flp variant to integrate 979
(691oxP/LL-CMV-EGFP -71FRT/FL-EF1a-puro-2A-DsRed) reporter into the native FL71362 target sequence in the intact HEK293 cells (Figure 3.5). For this, we modified the
979 reporter vector described in the previous section to include the constitutively
expressed inverted hygromycin B resistant gene under the control o f the PGK promoter
(Figure 3.5A) to help enrich the cell population containing the integrated vector.
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Figure 3.5: Hybrid TAL-Flp variant FV71 specific for the FRT-Iike sequence FL71
located in the human beta-globin gene can be used to deliver a reporter vector into
the gene in intact human cells. (A) Schematic o f the integration reaction. (B) The
characteristic PCR band is generated in the experimental but not in the control
integration reactions. Sequencing of the positive PCR band confirmed its identity.
The integration experiments were performed by co-transfecting the 979 reporter
vector and the TAL-Flp expression vector into HEK293 cells. In the control experiments
performed in parallel, the HEK293 cells were co-transfected with the 979 reporter vector
and the empty pOG expression vector. 48 hours post transfection, the cells were
expanded in the hygromycin supplemented medium for about a week and the ratio o f the
number o f green but not red colonies to other colonies (red and green, non colored, and
red but not green) was assessed. Then, the cells were collected and analyzed by PCR and
sequencing.
In the control experiments with the empty expression vector, the ratio o f the green
to other colonies was 0.87±1.62. In contrast, the ratio o f the green to other colonies in the
experiments with TAL-Flp was nearly similar: 0.95±0.23. The PCR analyses o f the
genomic DNA isolated from the collected cells showed that the characteristic,
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integration-specific bands were generated only when the cells were transfected with the
TAL-Flp variant expression vector but not with the empty one. The sequencing results o f
the integration-specific band confirmed the FL-71362 sequence obtained from the PCR
and also confirmed that site-specific integration had occurred.
3.2.6 Integration in HEK 293 Cells with Active
TAL-Cre M24- LV15/RV12 Variant
The integration experiment with the TAL-Cre-M24-LV15/RV12 variant was
performed three times in the HEK293 cells and the data presented below is from one of
the experiments that gave the positive result. The TAL-Cre-M24- LV15/RV12 variant
ability to integrate 979 (691oxP/LL-CMV-EGFP -71FRT/FL-EF1a-puro-2A-DsRed)
reporter into the native LL-69058 target sequence was tested in the intact HEK293 cells
(Figure 3.6). For this, the modified 979 reporter vector was used which is described in the
previous section. The modification was to include the constitutively expressed inverted
hygromycin B resistant gene under the control o f the PGK promoter (Figure 3.6) to help
enrich the cell population containing the integrated vector.

loxP/LL-69

^

A A

CV69

►

beta-globin gene yy y y

LL-69

LJ: ~0.8kb
8kb

LL-69

loxP/LL-69

Figure 3.6: Hybrid TAL-Cre-M24 variant specific for the loxP-Iike sequence LL-69
(abbreviation for LL-69058) located in the human beta-globin gene can be used to
deliver a reporter vector into the gene in intact human cells.

The integration experiments were performed by co-transfecting the 979 reporter
vector and the TAL-Cre-M24-LV15/RV12 expression vector into HEK293 cells. In the
control experiments performed in parallel, the HEK293 cells were co-transfected with the
979 reporter vector and the empty pOG expression vector. Forty eight hours post
transfection, the cells were expanded in the hygromycin supplemented medium for about
a week and the ratio o f the number o f red but not green colonies to other colonies (red
and green, non-colored, and green but not red) was assessed. Then, the cells were
collected and analyzed by PCR and sequencing.
In the control experiments with the empty expression vector, the ratio o f the red to
all other colonies was 0.142. In contrast, the ratio o f the red to all other in the
experiments with TAL-Cre-M24-LV15/RV12 was significantly lower: 0.087. The PCR
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analyses o f the genomic DNA isolated from the collected cells showed that the
characteristic, integration-specific bands were generated only when the cells were
transfected with the TAL-Cre-M24 variant expression vector but not with the empty one.
Sequencing o f the integration-specific bands confirmed the targeting o f the LL-69058
target sequence.
The overall goal o f the above experiments was to perform replacement reaction in
the model CHO and HEK293 mammalian cells with functional Cre variant that was able
to recognize the genomic LL-69058 target sequence. Variant TAL-Cre-M24-RV12/LV15
proved to be an active variant that could recognize the genomic site and efficiently
replace and integrate gene cassette into the genome.

CHAPTER 4

DISCUSSION

The power o f the tyrosine site-specific recombinases to edit genomes is widely
realized but only in the approaches that employ the pre-introduced cognate wild-type (or
essentially wild-type) recombination targets. The approaches that would utilize genomic
target-like sequences in their native chromosomal environment could add a valuable tool
to the genome engineering toolbox but are yet to be developed. The work presented in
this dissertation shows that the field can be advanced if genome manipulation methods
are developed around target-specific recombinase variants that are evolved to be active in
bacteria and further modified to optimize their expression level and their delivery into the
nucleus in the cells o f interest.
The performance o f FV7 in human HEK 293 cells did not mirror its performance in
hamster CHO cells: the integration efficiency o f FV7 in CHO cells was -0.1% o f the
transfected cells whereas it was only -0.01 % in HEK 293 cells. To improve the
integration activity of FV7 in human cells, we optimized the codons o f the FV7 gene to
maximize its expression in human cells and/or added the nuclear localization sequence to
the variant to enhance its ability to get into nucleus. The use o f the de novo evolved Flp
variant, FV9, which recombines FL-IL10A in E. coli slightly better than FV7, was also
helpful in increasing the efficiency o f FL-IL10A targeting.
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The effect o f the codon optimization on the integration activity o f FV7 and FV9 was
quite positive allowing the optimized variants, FV7o and FV9o, to have integration
activity over almost three-fold higher versus one-fold higher for FV7 and two-fold higher
for FV9 (Figure 3. IE). The activity increase was not uniform over the range o f the
expression plasmid inputs: the peaks o f the integration activity were detected at the
moderate input of the recombinase expression vectors. The codon optimization effect was
more pronounced for FV7: under optimal conditions, FV7o and FV9o were about 10 fold
and 5 fold more active than FV7 and FV9, respectively (Figure 3.IE).
The addition o f NLS to the original and to the codon-optimized recombinase variants
increased their integration activity: FV7 and FV9 showed a higher relative increase than
their ‘humanized’ versions while FV7o and FV9o showed higher absolute integration
activity (Figure 3. IE). The integration activity o f the NLS modified recombinase
variants, as well as the unmodified FV7o and FV9o, exhibited sharp dependence on the
input o f the respective recombinase expression vectors. The sharp peaks o f the
integration activity that depend on the recombinase input are not unusual for the tyrosine
recombinases and were noted before in the targeting experiments with the purified Cre
recombinase [57]. Such sharp peaks may reflect a narrow window o f the optimal
combination o f the efficiency o f the reversible integration-excision reactions and the
input of a recombinase.
The original and the ‘humanized’ NLS-modified Flp variants had different activity
patterns at the moderate input o f the recombinase expression vectors (the one that permits
the highest integration activity o f the recombinase variants (Figure 3.1 E). At this input,
FV7 and FV9 with N-terminal NLS showed higher integration activity than their C-
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terminal versions. In contrast, FV7o and FV9o variants showed the inverse activity
pattern: the variants with C-terminal NLS were more active than their N-terminal
counterparts (Figure 3. IE). Since the integration activity o f a recombinase in a cell was
found to depend not only on the actual ability o f this enzyme to recombine a particular
DNA sequence but also on the concentration o f the recombinase [57] and the timing o f its
expression [58]. The observed differences in the activity o f the NLS-modified variants
may be explained by the differences in the expression o f the variants and the timing of
their appearance in the nucleus. Indeed, the codon optimization and the addition o f NLS
can affect these parameters. Another factor to consider is a potential effect o f NLS and its
location on the actual enzymatic activity o f a recombinase variant.
Taken together, the codon optimization o f a recombinase gene, the addition o f NLS,
and the use of a more active Flp variant resulted in an approximately 35-fold increase in
the targeting efficiency o f FL-IL10A in human cells in the model setting: FV7 was able to
integrate a reporter in -0.01% o f the transfected cells while the ‘humanized’ version o f
FV9 with C-terminally placed NLS performed the task in -0.35% o f the transfected cells.
In the model setting o f human cells FV7 was capable o f targeting FL-IL10A
accurately: out o f ten randomly expanded integration-positive clones, only one clone had
vector integrated somewhere else in the genome, in addition to the correctly integrated
vector (Figure 3.1C).
Tyrosine recombinase variants that are specific for the genomic target-like sequences
are useful only if they are able to utilize these sequences in their native chromosomal
environment. Therefore, after improving the integration activity o f the Flp variants in
human cells in the model setting, we tested whether these variants can recombine the FL-
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IL10A sequence in its native chromosomal environment in the unmodified human cells.
The successful targeting o f FL-IL10A demonstrated that sequence specific Flp variants
are indeed capable o f accomplishing the task (Figure 3.2). To our knowledge, similar
results for tyrosine recombinases have not been demonstrated before. Indeed, in the
earlier report, a Cre variant evolved to recombine a loxP-like sequence in the LTRs o f
FIIV-1 was shown to target this sequence in the human cells [59], However, since a copy
of the HIV-1 pseudotype genome used in that study was randomly integrated and stably
maintained in the human cells, the resultant HIV-1 provirus should be considered a pre
introduced model recombination reporter, functionally equivalent to any model
recombination reporter for this matter. Therefore, although quite remarkable, the
experiments described by Sarkar et al. [59] do not demonstrate that tyrosine
recombinases variants are able to utilize genomic target-like sequences in their native
chromosomal locale.
The performance o f TAL-Cre-M24 against just plain Cre-M24 was tested in the
bacterial, CHO model cells and HEK293 cells for efficient recombination activity.
Though the experimental attempts with plain Cre-M24 were unsuccessful in all the three
screening systems, when Cre-M24 was fused to the TAL-core DNA-binding domain
recombination sufficient activity was observed. The other Cre variants listed in Table 3.2
had various mutations at the DNA-recombinase interaction points, and were also
screened through the bacterial and CHO model cell systems. The random mutations in the
Cre variants were such that it would loosen the complexity with which the Cre monomermonomer interact or Cre-DNA interact leading to a flexible approach for them to
recognize the target sequence. These variants were screened with and without attachment
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o f TAL-core DNA-binding domain, but all attempts to achieve minimal recombination
activity failed. There were a few green/red colonies observed with TAL-core DNAbinding domain variant, but the green color always faded in the colonies on expansion. I
am not sure about any particular reason behind the fading o f green color, but there can be
silencing o f the EGFP gene when the reporter and expression plasmids are present in the
same cell either activating or suppressing certain pathways or there can be random
integrations in the genome that cause the EGFP to lose its expression in the cells. TALCre-M24 was the only active variant we attained from all the directed evolution protocols
that showed 0.1% replacement activity in the CHO model cells.
The initial construction o f TAL-Cre-M24 consisted o f 18 nucleotide RVD's
assembled on left and right arms o f DNA-binding domains. Half spacer region was used
to fuse the Cre and the TAL-core DNA-binding domains. There was a minimal
recombination activity observed in the bacterial and CHO model cells. On an average just
one green/red colony was observed every transfection reaction. Attempts were made to
have better replacement activity in CHO model cells by modifying the TAL-core, the
DNA-binding domains o f TAL-Cre-M24 variant and the linker region present between
the Cre and TAL-core DNA-binding domain. Various combinations o f the TAL core
ranging from 117+95,117+63 and 117+28 C to N terminal were tested in the model cells.
There was a two-fold difference in activity amongst the TAL-core with 117+95 TALcore being highly efficient. Thus the decision we made o f using TAL-core 117+95 in
previous experiments was helpful. We also observed that half linker region proved to be a
better match between the TAL-core DNA-binding region and Cre-M24 variant as it
provided enough flexibility to Cre-M24 to recognize and bind at the genomic LL-69058
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target sequence. H alf linker regions had two-fold better activity compared with one and
full linker spacer regions.
Furthermore, out o f the various DNA-binding domain arms, the combination o f 15
and 12 RVD's on the left and right arm respectively, proved to be highly efficient when
fused with Cre-M24 variant, increasing the recombination activity by five-fold in the
model cells. Thus the new version: TALE-117+95-Half linker-Cre-M24, left LV15 and
right RV12 combination was 5-fold more efficient than the old version: TAL-117+95H alf linker-Cre-M24, left LV18 and right RV18. The new version TAL-117+95-Half
linker-Cre-M24 is referred to as TAL-Cre-M24-LV15/RV12 in all my experiments.
Overall it was observed that the major increase in the recombination efficiency was
basically due to the change in the DNA-binding domain arms. As the arms were
shortened to 15 and 12 nucleotides, they tended to improve by the replacement efficiency
by 0.58%. The mutation at the 24th position in the Cre gene helped in releasing the tight
bonding between the monomer-monomer protein subunits and when the Cre-M24 variant
is cloned with the shorter arms o f TAL-domans, it becomes feasible for the recombinase
to bind at the LL-69058 target sequence. As the arms are short and closer to the target
sequence (Figure 3.4 D) they bind firmly to the DNA giving full access and flexibility to
the Cre recombinase with half linker region. As we have seen in control experiments,
plain Cre-M24 just did not show any recombination activity. Thus only when Cre-M24 is
bonded to TAL-domain does it serve our purpose.
In the next experiments we tested the TAL-Cre-M24-LV15/RV12 variant in the
native genomic environment. As the experiment was performed just once, the data
represented here is from one time PCR analysis and sequencing. The TAL-Cre-M24
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variant successfully integrated at the genomic LL-69058 target sequence (Figure 3.6).
The results were confirmed through sequencing o f the correct size (-800 bp) PCR band.
More TAL-Cre-M24 based integration experiments in the HEK293 cells are to be
performed in the future to confirm the results. TAL-Flp variant was also tested for its
recombination efficiency in the native genomic environment in the FIEK293 cells.
Several integration experiments were performed and it was observed that TAL-Flp
variant recognizes the genomic FL-71362 as confirmed by PCR band size and
sequencing. Therefore, both the evolved TAL-Cre-M24 and TAL-Flp recombinases can
recognize the genomic target sequences separately when tested in the human cells.
Future experiments aim at using both the evolved TAL-Cre-M24 and TAL-Flp
recombinases simultaneously by co-transfecting them along with the reporter plasmid to
recognize the genomic LL-69058 and FL-71362 target sequences and perform successful
replacement o f the gene cassette in the native genomic environment. Various
concentrations o f the recombinases are to be tested and optimized to have consistent
replacement. If the dual RMCE attempt is successful in the genomic environment then we
can prove to have a potential cure for the sickle cell disease. As the genomic target
sequences LL-69058 and FL-71362 flank the beta-globin gene that consists the mutation
causing sickle cell disease, replacing the gene cassette between the two target sequences
would replace the mutated region with a normal gene region. It could be used as gene
therapy for sickle cell disease. This fundamental approach o f evolving recombinases to
recognize genomic target-like sequences, can also be applied to cure other diseases that
tend to possess recombinase target-like sequences in their vicinity in the human genome.

APPENDIX

SUPPLEMENTAL FIGURES AND SEQUENCES
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Figure A .l: Sequencing results snapshot of the FV7-mediated integration product of
the incoming reporter into FL-IL10A located in the platform reporter pre
integrated into the HEK 293 genome (see Figure 3.1). (A) Schematic of the
integration product. The horizontal green and red bars represent the diagnostic
PCR products at the left junction (LJ) and the right junction (RJ) of the integration
product. (B) The sequencing results snapshots of the respective PCR products are
shown below the schematics o f the resultant recombination sites and the
surrounding sequences.
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Protein alignment of the whole sequences for iCreM 32-iCre262-l, 14,21.
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Figure A.2: Protein sequence alignments of Cre-M24, Cre262-1, Cre262-14 and
Cre262-21 using Clustal Omega software. The stars below the sequence indicate
match in amino acids while a dot indicate a mutation in the protein sequence. The
location of the amino acid can be determined by the numbers present at the end of
the sequence.
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